Innovent Organized a Forum Discussing the Pending Launch of its Anti PD-1 Tyvyt® (Sintilimab injection) as Part of the National Mega Innovation Program in Beijing

BEIJING, Feb. 22, 2019 /PRNewswire/ — The Forum for the National Mega Innovation Program in conjunction with the press conference on the launch of Tyvyt® (fully human anti-PD-1 therapeutic monoclonal antibody, generic name: sintilimab injection), hosted by Innovent Biologics, Inc. (Innovent) (HKEX: 01801), and co-sponsored by the China Association of Productivity Promotion Centers (CAPPC), was successfully held in Beijing today. During the press conference, Innovent also announced the launch of the Clinical Oncology Research Fund, jointly initiated by the Beijing Xisike Clinical Oncology Research Foundation and Innovent, which encourages doctors to conduct more translational research in oncology and to improve their skills in ...

Gepostet in der Kategorie Wirtschaft (Anzahl der ansichten:) 5

Ähnlich Nachrichten